Antimyostatin Treatment: Comparison
View Latest Version
Please note this is a comparison between Version 2 by Camila Xu and Version 1 by Tue Nielsen.

Myostatin, also known as growth and differentiation factor 8 (GDF-8), was identified in 1997 by McPherron and Lee.

  • myostatin
  • muscular dystrophy
  • muscular regeneration
  • ActRIIB
  • TGF-β
Please wait, diff process is still running!

References

  1. McPherron, A.C.; Lawler, A.M.; Lee, S.-J. Regulation of Skeletal Muscle Mass in Mice by a New TGF-p Superfamily Member. Nature 1997, 387, 83–90.
  2. Grobet, L.; Martin, L.J.; Poncelet, D.; Pirottin, D.; Brouwers, B.; Riquet, J.; Schoeberlein, A.; Dunner, S.; Ménissier, F.; Massabanda, J.; et al. A Deletion in the Bovine Myostatin Gene Causes the Double-Muscled Phenotype in Cattle. Nat. Genet. 1997, 17, 71–74.
  3. Kambadur, R.; Sharma, M.; Smith, T.P.; Bass, J.J. Mutations in Myostatin (GDF8) in Double-Muscled Belgian Blue and Piedmontese Cattle. Genome Res. 1997, 7, 910–916.
  4. McPherron, A.C.; Lee, S.J. Double Muscling in Cattle Due to Mutations in the Myostatin Gene. Proc. Natl. Acad. Sci. USA 1997, 94, 12457–12461.
  5. Mosher, D.S.; Quignon, P.; Bustamante, C.D.; Sutter, N.B.; Mellersh, C.S.; Parker, H.G.; Ostrander, E.A. A Mutation in the Myostatin Gene Increases Muscle Mass and Enhances Racing Performance in Heterozygote Dogs. PLoS Genet. 2007, 3.
  6. Schuelke, M.; Wagner, K.R.; Stolz, L.E.; Hübner, C.; Riebel, T.; Kömen, W.; Braun, T.; Tobin, J.F.; Lee, S.-J. Myostatin Mutation Associated with Gross Muscle Hypertrophy in a Child. N. Engl. J. Med. 2004, 350, 2682–2688.
  7. Mendias, C.L.; Bakhurin, K.I.; Gumucio, J.P.; Shallal-Ayzin, M.V.; Davis, C.S.; Faulkner, J.A. Haploinsufficiency of Myostatin Protects against Aging-Related Declines in Muscle Function and Enhances the Longevity of Mice. Aging Cell 2015, 14, 704–706.
  8. Morissette, M.R.; Stricker, J.C.; Rosenberg, M.A.; Buranasombati, C.; Levitan, E.B.; Mittleman, M.A.; Rosenzweig, A. Effects of Myostatin Deletion in Aging Mice. Aging Cell 2009, 8, 573–583.
  9. Amthor, H.; Huang, R.; McKinnell, I.; Christ, B.; Kambadur, R.; Sharma, M.; Patel, K. The Regulation and Action of Myostatin as a Negative Regulator of Muscle Development during Avian Embryogenesis. Dev. Biol. 2002, 251, 241–257.
  10. Manceau, M.; Gros, J.; Savage, K.; Thomé, V.; McPherron, A.; Paterson, B.; Marcelle, C. Myostatin Promotes the Terminal Differentiation of Embryonic Muscle Progenitors. Genes Dev. 2008, 22, 668–681.
  11. Hill, J.J.; Davies, M.V.; Pearson, A.A.; Wang, J.H.; Hewick, R.M.; Wolfman, N.M.; Qiu, Y. The Myostatin Propeptide and the Follistatin-Related Gene Are Inhibitory Binding Proteins of Myostatin in Normal Serum. J. Biol. Chem. 2002, 277, 40735–40741.
  12. Sharma, M.; Kambadur, R.; Matthews, K.G.; Somers, W.G.; Devlin, G.P.; Conaglen, J.V.; Fowke, P.J.; Bass, J.J. Myostatin, a Transforming Growth Factor-β Superfamily Member, Is Expressed in Heart Muscle and Is Upregulated in Cardiomyocytes after Infarct. J. Cell. Physiol. 1999, 180, 1–9.
  13. Gonzalez-Cadavid, N.F.; Taylor, W.E.; Yarasheski, K.; Sinha-Hikim, I.; Ma, K.; Ezzat, S.; Shen, R.; Lalani, R.; Asa, S.; Mamita, M.; et al. Organization of the Human Myostatin Gene and Expression in Healthy Men and HIV-Infected Men with Muscle Wasting. Proc. Natl. Acad. Sci. USA 1998, 95, 14938–14943.
  14. Rodgers, B.D.; Weber, G.M. Sequence Conservation among Fish Myostatin Orthologues and the Characterization of Two Additional CDNA Clones from Morone Saxatilis and Morone Americana. Comp. Biochem. Physiol. Bbiochem. Mol. Biol. 2001, 129, 597–603.
  15. Smith, T.P.; Lopez-Corrales, N.L.; Kappes, S.M.; Sonstegard, T.S. Myostatin Maps to the Interval Containing the Bovine Mh Locus. Mamm. Genome 1997, 8, 742–744.
  16. Stavaux, D.; Art, T.; McEntee, K.; Reznick, M.; Lekeux, P. Muscle Fibre Type and Size, and Muscle Capillary Density in Young Double-Muscled Blue Belgian Cattle. Zent. Vet. A 1994, 41, 229–236.
  17. Lee, S.-J.; McPherron, A.C. Regulation of Myostatin Activity and Muscle Growth. Proc. Natl. Acad. Sci. USA 2001, 98, 9306–9311.
  18. Thies, R.S.; Chen, T.; Davies, M.V.; Tomkinson, K.N.; Pearson, A.A.; Shakey, Q.A.; Wolfman, N.M. GDF-8 Propeptide Binds to GDF-8 and Antagonizes Biological Activity by Inhibiting GDF-8 Receptor Binding. Growth Factors 2001, 18, 251–259.
  19. Wolfman, N.M.; McPherron, A.C.; Pappano, W.N.; Davies, M.V.; Song, K.; Tomkinson, K.N.; Wright, J.F.; Zhao, L.; Sebald, S.M.; Greenspan, D.S.; et al. Activation of Latent Myostatin by the BMP-1/Tolloid Family of Metalloproteinases. Proc. Natl. Acad. Sci. USA 2003, 100, 15842–15846.
  20. Lee, S.-J. Genetic Analysis of the Role of Proteolysis in the Activation of Latent Myostatin. PLoS ONE 2008, 3.
  21. Amthor, H.; Nicholas, G.; McKinnell, I.; Kemp, C.F.; Sharma, M.; Kambadur, R.; Patel, K. Follistatin Complexes Myostatin and Antagonises Myostatin-Mediated Inhibition of Myogenesis. Dev. Biol. 2004, 270, 19–30.
  22. Hill, J.J.; Qiu, Y.; Hewick, R.M.; Wolfman, N.M. Regulation of Myostatin in Vivo by Growth and Differentiation Factor-Associated Serum Protein-1: A Novel Protein with Protease Inhibitor and Follistatin Domains. Mol. Endocrinol. 2003, 17, 1144–1154.
  23. Miura, T.; Kishioka, Y.; Wakamatsu, J.; Hattori, A.; Hennebry, A.; Berry, C.J.; Sharma, M.; Kambadur, R.; Nishimura, T. Decorin Binds Myostatin and Modulates Its Activity to Muscle Cells. Biochem. Biophys. Res. Commun. 2006, 340, 675–680.
  24. Zhu, J.; Li, Y.; Shen, W.; Qiao, C.; Ambrosio, F.; Lavasani, M.; Nozaki, M.; Branca, M.F.; Huard, J. Relationships between Transforming Growth Factor-Β1, Myostatin, and Decorin Implications for Skeletal Muscle Fibrosis. J. Biol. Chem. 2007, 282, 25852–25863.
  25. Kemaladewi, D.U.; de Gorter, D.J.J.; Aartsma-Rus, A.; van Ommen, G.-J.; ten Dijke, P.; ’t Hoen, P.A.C.; Hoogaars, W.M. Cell-Type Specific Regulation of Myostatin Signaling. FASEB J. 2012, 26, 1462–1472.
  26. Rebbapragada, A.; Benchabane, H.; Wrana, J.L.; Celeste, A.J.; Attisano, L. Myostatin Signals through a Transforming Growth Factor β-Like Signaling Pathway To Block Adipogenesis. Mol. Cell Biol. 2003, 23, 7230–7242.
  27. Derynck, R.; Zhang, Y.E. Smad-Dependent and Smad-Independent Pathways in TGF-Beta Family Signalling. Nature 2003, 425, 577–584.
  28. Langley, B.; Thomas, M.; Bishop, A.; Sharma, M.; Gilmour, S.; Kambadur, R. Myostatin Inhibits Myoblast Differentiation by Down-Regulating MyoD Expression. J. Biol. Chem. 2002, 277, 49831–49840.
  29. Thomas, M.; Langley, B.; Berry, C.; Sharma, M.; Kirk, S.; Bass, J.; Kambadur, R. Myostatin, a Negative Regulator of Muscle Growth, Functions by Inhibiting Myoblast Proliferation. J. Biol. Chem. 2000, 275, 40235–40243.
  30. Sartori, R.; Schirwis, E.; Blaauw, B.; Bortolanza, S.; Zhao, J.; Enzo, E.; Stantzou, A.; Mouisel, E.; Toniolo, L.; Ferry, A.; et al. BMP Signaling Controls Muscle Mass. Nat. Genet. 2013, 45, 1309–1318.
  31. Biesemann, N.; Mendler, L.; Wietelmann, A.; Hermann, S.; Schäfers, M.; Krüger, M.; Boettger, T.; Borchardt, T.; Braun, T. Myostatin Regulates Energy Homeostasis in the Heart and Prevents Heart Failure. Circ. Res. 2014, 115, 296–310.
  32. Philip, B.; Lu, Z.; Gao, Y. Regulation of GDF-8 Signaling by the P38 MAPK. Cell Signal. 2005, 17, 365–375.
  33. Ratkevicius, A.; Joyson, A.; Selmer, I.; Dhanani, T.; Grierson, C.; Tommasi, A.M.; DeVries, A.; Rauchhaus, P.; Crowther, D.; Alesci, S.; et al. Serum Concentrations of Myostatin and Myostatin-Interacting Proteins Do Not Differ between Young and Sarcopenic Elderly Men. J. Gerontol. A Biol. Sci. Med. Sci. 2011, 66, 620–626.
  34. Burch, P.M.; Pogoryelova, O.; Palandra, J.; Goldstein, R.; Bennett, D.; Fitz, L.; Guglieri, M.; Bettolo, C.M.; Straub, V.; Evangelista, T.; et al. Reduced Serum Myostatin Concentrations Associated with Genetic Muscle Disease Progression. J. Neurol. 2017, 264, 541–553.
  35. Szulc, P.; Schoppet, M.; Goettsch, C.; Rauner, M.; Dschietzig, T.; Chapurlat, R.; Hofbauer, L.C. Endocrine and Clinical Correlates of Myostatin Serum Concentration in Men--the STRAMBO Study. J. Clin. Endocrinol Metab. 2012, 97, 3700–3708.
  36. Lakshman, K.M.; Bhasin, S.; Corcoran, C.; Collins-Racie, L.A.; Tchistiakova, L.; Forlow, S.B.; St Ledger, K.; Burczynski, M.E.; Dorner, A.J.; Lavallie, E.R. Measurement of Myostatin Concentrations in Human Serum: Circulating Concentrations in Young and Older Men and Effects of Testosterone Administration. Mol. Cell Endocrinol. 2009, 302, 26–32.
  37. Schafer, M.J.; Atkinson, E.J.; Vanderboom, P.M.; Kotajarvi, B.; White, T.A.; Moore, M.M.; Bruce, C.J.; Greason, K.L.; Suri, R.M.; Khosla, S.; et al. Quantification of GDF11 and Myostatin in Human Aging and Cardiovascular Disease. Cell Metab. 2016, 23, 1207–1215.
  38. Raue, U.; Slivka, D.; Jemiolo, B.; Hollon, C.; Trappe, S. Myogenic Gene Expression at Rest and after a Bout of Resistance Exercise in Young (18–30 Yr) and Old (80–89 Yr) Women. J. Appl. Physiol. 2006, 101, 53–59.
  39. Chew, J.; Tay, L.; Lim, J.P.; Leung, B.P.; Yeo, A.; Yew, S.; Ding, Y.Y.; Lim, W.S. Serum Myostatin and IGF-1 as Gender-Specific Biomarkers of Frailty and Low Muscle Mass in Community-Dwelling Older Adults. J. Nutr. Health Aging 2019, 23, 979–986.
  40. Christensen, H.M.; Kistorp, C.; Schou, M.; Keller, N.; Zerahn, B.; Frystyk, J.; Schwarz, P.; Faber, J. Prevalence of Cachexia in Chronic Heart Failure and Characteristics of Body Composition and Metabolic Status. Endocrine 2013, 43, 626–634.
  41. Peng, L.-N.; Lee, W.-J.; Liu, L.-K.; Lin, M.-H.; Chen, L.-K. Healthy Community-Living Older Men Differ from Women in Associations between Myostatin Levels and Skeletal Muscle Mass. J. Cachexia Sarcopenia Muscle 2018, 9, 635–642.
  42. Bagheri, R.; Moghadam, B.H.; Church, D.D.; Tinsley, G.M.; Eskandari, M.; Moghadam, B.H.; Motevalli, M.S.; Baker, J.S.; Robergs, R.A.; Wong, A. The Effects of Concurrent Training Order on Body Composition and Serum Concentrations of Follistatin, Myostatin and GDF11 in Sarcopenic Elderly Men. Exp. Gerontol. 2020, 133, 110869.
  43. Negaresh, R.; Ranjbar, R.; Baker, J.; Habibi, A.; Mokhtarzade, M.; Gharibvand, M.; Fokin, A. Skeletal Muscle Hypertrophy, Insulin-like Growth Factor 1, Myostatin and Follistatin in Healthy and Sarcopenic Elderly Men: The Effect of Whole-Body Resistance Training. Int. J. Prev. Med. 2019, 10, 29.
  44. Zimmers, T.A.; Davies, M.V.; Koniaris, L.G.; Haynes, P.; Esquela, A.F.; Tomkinson, K.N.; McPherron, A.C.; Wolfman, N.M.; Lee, S.-J. Induction of Cachexia in Mice by Systemically Administered Myostatin. Science 2002, 296, 1486–1488.
  45. Lenk, K.; Schuler, G.; Adams, V. Skeletal Muscle Wasting in Cachexia and Sarcopenia: Molecular Pathophysiology and Impact of Exercise Training. J. Cachexia Sarcopenia Muscle 2010, 1, 9–21.
  46. Shyu, K.G.; Lu, M.J.; Wang, B.W.; Sun, H.Y.; Chang, H. Myostatin Expression in Ventricular Myocardium in a Rat Model of Volume-Overload Heart Failure. Eur. J. Clin. Investig. 2006, 36, 713–719.
  47. Lenk, K.; Schur, R.; Linke, A.; Erbs, S.; Matsumoto, Y.; Adams, V.; Schuler, G. Impact of Exercise Training on Myostatin Expression in the Myocardium and Skeletal Muscle in a Chronic Heart Failure Model. Eur. J. Heart Fail. 2009, 11, 342–348.
  48. Lenk, K.; Erbs, S.; Höllriegel, R.; Beck, E.; Linke, A.; Gielen, S.; Winkler, S.M.; Sandri, M.; Hambrecht, R.; Schuler, G.; et al. Exercise Training Leads to a Reduction of Elevated Myostatin Levels in Patients with Chronic Heart Failure. Eur. J. Prev. Cardiol. 2012, 19, 404–411.
  49. George, I.; Bish, L.T.; Kamalakkannan, G.; Petrilli, C.M.; Oz, M.C.; Naka, Y.; Lee Sweeney, H.; Maybaum, S. Myostatin Activation in Patients with Advanced Heart Failure and after Mechanical Unloading. Eur. J. Heart Fail. 2010, 12, 444–453.
  50. Gruson, D.; Ahn, S.A.; Ketelslegers, J.-M.; Rousseau, M.F. Increased Plasma Myostatin in Heart Failure. Eur. J. Heart Fail. 2011, 13, 734–736.
  51. Zamora, E.; Simó, R.; Lupón, J.; Galán, A.; Urrutia, A.; González, B.; Mas, D.; Valle, V. Serum Myostatin Levels in Chronic Heart Failure. Rev. Esp. Cardiol. 2010, 63, 992–996.
  52. Furihata, T.; Kinugawa, S.; Fukushima, A.; Takada, S.; Homma, T.; Masaki, Y.; Abe, T.; Yokota, T.; Oba, K.; Okita, K.; et al. Serum Myostatin Levels Are Independently Associated with Skeletal Muscle Wasting in Patients with Heart Failure. Int. J. Cardiol. 2016, 220, 483–487.
  53. Wintgens, K.F.; Dschietzig, T.; Stoeva, S.; Paulsson, M.; Armbruster, F.P. Plasma Myostatin Measured by a Competitive ELISA Using a Highly Specific Antiserum. Clin. Chim. Acta 2012, 413, 1288–1294.
  54. Costelli, P.; Muscaritoli, M.; Bonetto, A.; Penna, F.; Reffo, P.; Bossola, M.; Bonelli, G.; Doglietto, G.B.; Baccino, F.M.; Fanelli, F.R. Muscle Myostatin Signalling Is Enhanced in Experimental Cancer Cachexia. Eur. J. Clin. Investig. 2008, 38, 531–538.
  55. Zhou, X.; Wang, J.L.; Lu, J.; Song, Y.; Kwak, K.S.; Jiao, Q.; Rosenfeld, R.; Chen, Q.; Boone, T.; Simonet, W.S.; et al. Reversal of Cancer Cachexia and Muscle Wasting by ActRIIB Antagonism Leads to Prolonged Survival. Cell 2010, 142, 531–543.
  56. Murphy, K.T.; Chee, A.; Gleeson, B.G.; Naim, T.; Swiderski, K.; Koopman, R.; Lynch, G.S. Antibody-Directed Myostatin Inhibition Enhances Muscle Mass and Function in Tumor-Bearing Mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2011, 301, R716–726.
  57. Sharma, M.; McFarlane, C.; Kambadur, R.; Kukreti, H.; Bonala, S.; Srinivasan, S. Myostatin: Expanding Horizons: Myostatin. Iubmb Life 2015, 67, 589–600.
  58. Hayot, M.; Rodriguez, J.; Vernus, B.; Carnac, G.; Jean, E.; Allen, D.; Goret, L.; Obert, P.; Candau, R.; Bonnieu, A. Myostatin Up-Regulation Is Associated with the Skeletal Muscle Response to Hypoxic Stimuli. Mol. Cell. Endocrinol. 2011, 332, 38–47.
  59. Plant, P.J.; Brooks, D.; Faughnan, M.; Bayley, T.; Bain, J.; Singer, L.; Correa, J.; Pearce, D.; Binnie, M.; Batt, J. Cellular Markers of Muscle Atrophy in Chronic Obstructive Pulmonary Disease. Am. J. Respir. Cell Mol. Biol. 2010, 42, 461–471.
  60. Ju, C.-R.; Chen, R.-C. Serum Myostatin Levels and Skeletal Muscle Wasting in Chronic Obstructive Pulmonary Disease. Respir. Med. 2012, 106, 102–108.
  61. Avin, K.G.; Chen, N.X.; Organ, J.M.; Zarse, C.; O’Neill, K.; Conway, R.G.; Konrad, R.J.; Bacallao, R.L.; Allen, M.R.; Moe, S.M. Skeletal Muscle Regeneration and Oxidative Stress Are Altered in Chronic Kidney Disease. PLoS ONE 2016, 11, e0159411.
  62. Jones, S.W.; Hill, R.J.; Krasney, P.A.; O’Conner, B.; Peirce, N.; Greenhaff, P.L. Disuse Atrophy and Exercise Rehabilitation in Humans Profoundly Affects the Expression of Genes Associated with the Regulation of Skeletal Muscle Mass. FASEB J. 2004, 18, 1025–1027.
  63. Kim, J.; Cross, J.M.; Bamman, M.M. Impact of Resistance Loading on Myostatin Expression and Cell Cycle Regulation in Young and Older Men and Women. Am. J. Physiol.-Endocrinol. Metab. 2005, 288, E1110–E1119.
  64. Louis, E.; Raue, U.; Yang, Y.; Jemiolo, B.; Trappe, S. Time Course of Proteolytic, Cytokine, and Myostatin Gene Expression after Acute Exercise in Human Skeletal Muscle. J. Appl. Physiol. 2007, 103, 1744–1751.
  65. Hittel, D.S.; Axelson, M.; Sarna, N.; Shearer, J.; Huffman, K.M.; Kraus, W.E. Myostatin Decreases with Aerobic Exercise and Associates with Insulin Resistance. Med. Sci. Sports Exerc. 2010, 42, 2023–2029.
  66. Whittemore, L.-A.; Song, K.; Li, X.; Aghajanian, J.; Davies, M.; Girgenrath, S.; Hill, J.J.; Jalenak, M.; Kelley, P.; Knight, A.; et al. Inhibition of Myostatin in Adult Mice Increases Skeletal Muscle Mass and Strength. Biochem. Biophys. Res. Commun. 2003, 300, 965–971.
  67. Smith, R.C.; Cramer, M.S.; Mitchell, P.J.; Lucchesi, J.; Ortega, A.M.; Livingston, E.W.; Ballard, D.; Zhang, L.; Hanson, J.; Barton, K.; et al. Inhibition of Myostatin Prevents Microgravity-Induced Loss of Skeletal Muscle Mass and Strength. PLoS ONE 2020, 15.
  68. Pirruccello-Straub, M.; Jackson, J.; Wawersik, S.; Webster, M.T.; Salta, L.; Long, K.; McConaughy, W.; Capili, A.; Boston, C.; Carven, G.J.; et al. Blocking Extracellular Activation of Myostatin as a Strategy for Treating Muscle Wasting. Sci. Rep. 2018, 8.
  69. Camporez, J.-P.G.; Petersen, M.C.; Abudukadier, A.; Moreira, G.V.; Jurczak, M.J.; Friedman, G.; Haqq, C.M.; Petersen, K.F.; Shulman, G.I. Anti-Myostatin Antibody Increases Muscle Mass and Strength and Improves Insulin Sensitivity in Old Mice. Proc. Natl. Acad. Sci. USA 2016, 113, 2212–2217.
  70. Muramatsu, H.; Kuramochi, T.; Katada, H.; Ueyama, A.; Ruike, Y.; Ohmine, K.; Shida-Kawazoe, M.; Miyano-Nishizawa, R.; Shimizu, Y.; Okuda, M.; et al. Novel Myostatin-Specific Antibody Enhances Muscle Strength in Muscle Disease Models. Sci. Rep. 2021, 11, 2160.
  71. St. Andre, M.; Johnson, M.; Bansal, P.N.; Wellen, J.; Robertson, A.; Opsahl, A.; Burch, P.M.; Bialek, P.; Morris, C.; Owens, J. A Mouse Anti-Myostatin Antibody Increases Muscle Mass and Improves Muscle Strength and Contractility in the Mdx Mouse Model of Duchenne Muscular Dystrophy and Its Humanized Equivalent, Domagrozumab (PF-06252616), Increases Muscle Volume in Cynomolgus Monkeys. Skelet. Muscle 2017, 7, 25.
  72. Bogdanovich, S.; Krag, T.O.B.; Barton, E.R.; Morris, L.D.; Whittemore, L.-A.; Ahima, R.S.; Khurana, T.S. Functional Improvement of Dystrophic Muscle by Myostatin Blockade. Nature 2002, 420, 418–421.
  73. Bogdanovich, S.; McNally, E.M.; Khurana, T.S. Myostatin Blockade Improves Function but Not Histopathology in a Murine Model of Limb-Girdle Muscular Dystrophy 2C. Muscle Nerve 2008, 37, 308–316.
  74. Parsons, S.A.; Millay, D.P.; Sargent, M.A.; McNally, E.M.; Molkentin, J.D. Age-Dependent Effect of Myostatin Blockade on Disease Severity in a Murine Model of Limb-Girdle Muscular Dystrophy. Am. J. Pathol. 2006, 168, 1975–1985.
  75. Murphy, K.T.; Ryall, J.G.; Snell, S.M.; Nair, L.; Koopman, R.; Krasney, P.A.; Ibebunjo, C.; Holden, K.S.; Loria, P.M.; Salatto, C.T.; et al. Antibody-Directed Myostatin Inhibition Improves Diaphragm Pathology in Young but Not Adult Dystrophic Mdx Mice. Am. J. Pathol. 2010, 176, 2425–2434.
  76. Harish, P.; Malerba, A.; Lu-Nguyen, N.; Forrest, L.; Cappellari, O.; Roth, F.; Trollet, C.; Popplewell, L.; Dickson, G. Inhibition of Myostatin Improves Muscle Atrophy in Oculopharyngeal Muscular Dystrophy (OPMD). J. Cachexia Sarcopenia Muscle 2019, 10, 1016–1026.
  77. Tinklenberg, J.A.; Siebers, E.M.; Beatka, M.J.; Meng, H.; Yang, L.; Zhang, Z.; Ross, J.A.; Ochala, J.; Morris, C.; Owens, J.M.; et al. Myostatin Inhibition Using MRK35 Produces Skeletal Muscle Growth and Tubular Aggregate Formation in Wild Type and TgACTA1D286G Nemaline Myopathy Mice. Hum. Mol. Genet. 2018, 27, 638–648.
  78. Weng, S.; Gao, F.; Wang, J.; Li, X.; Chu, B.; Wang, J.; Yang, G. Improvement of Muscular Atrophy by AAV-SaCas9-Mediated Myostatin Gene Editing in Aged Mice. Cancer Gene 2020, 27, 960–975.
  79. Holzbaur, E.L.F.; Howland, D.S.; Weber, N.; Wallace, K.; She, Y.; Kwak, S.; Tchistiakova, L.A.; Murphy, E.; Hinson, J.; Karim, R.; et al. Myostatin Inhibition Slows Muscle Atrophy in Rodent Models of Amyotrophic Lateral Sclerosis. Neurobiol. Dis. 2006, 23, 697–707.
  80. Harish, P.; Forrest, L.; Herath, S.; Dickson, G.; Malerba, A.; Popplewell, L. Inhibition of Myostatin Reduces Collagen Deposition in a Mouse Model of Oculopharyngeal Muscular Dystrophy (OPMD) With Established Disease. Front. Physiol. 2020, 11, 184.
  81. Latres, E.; Pangilinan, J.; Miloscio, L.; Bauerlein, R.; Na, E.; Potocky, T.B.; Huang, Y.; Eckersdorff, M.; Rafique, A.; Mastaitis, J.; et al. Myostatin Blockade with a Fully Human Monoclonal Antibody Induces Muscle Hypertrophy and Reverses Muscle Atrophy in Young and Aged Mice. Skelet Muscle 2015, 5.
  82. Singh, P.; Rong, H.; Gordi, T.; Bosley, J.; Bhattacharya, I. Translational Pharmacokinetic/Pharmacodynamic Analysis of MYO-029 Antibody for Muscular Dystrophy. Clin. Transl. Sci. 2016, 9, 302–310.
  83. Bogdanovich, S.; Perkins, K.J.; Krag, T.O.B.; Whittemore, L.-A.; Khurana, T.S. Myostatin Propeptide-Mediated Amelioration of Dystrophic Pathophysiology. FASEB J. 2005, 19, 543–549.
  84. Qiao, C.; Li, J.; Jiang, J.; Zhu, X.; Wang, B.; Li, J.; Xiao, X. Myostatin Propeptide Gene Delivery by Adeno-Associated Virus Serotype 8 Vectors Enhances Muscle Growth and Ameliorates Dystrophic Phenotypes in Mdx Mice. Hum. Gene Ther. 2008, 19, 241–254.
  85. Bartoli, M.; Poupiot, J.; Vulin, A.; Fougerousse, F.; Arandel, L.; Daniele, N.; Roudaut, C.; Noulet, F.; Garcia, L.; Danos, O.; et al. AAV-Mediated Delivery of a Mutated Myostatin Propeptide Ameliorates Calpain 3 but Not α -Sarcoglycan Deficiency. Gene Ther. 2007, 14, 733–740.
  86. Akpan, I.; Goncalves, M.D.; Dhir, R.; Yin, X.; Pistilli, E.E.; Bogdanovich, S.; Khurana, T.S.; Ucran, J.; Lachey, J.; Ahima, R.S. The Effects of a Soluble Activin Type IIB Receptor on Obesity and Insulin Sensitivity. Int. J. Obes. 2009, 33, 1265–1273.
  87. Chiu, C.-S.; Peekhaus, N.; Weber, H.; Adamski, S.; Murray, E.M.; Zhang, H.Z.; Zhao, J.Z.; Ernst, R.; Lineberger, J.; Huang, L.; et al. Increased Muscle Force Production and Bone Mineral Density in ActRIIB-Fc-Treated Mature Rodents. J. Gerontol. Ser. A Biol. Sci. Med. Sci. 2013, 68, 1181–1192.
  88. Cadena, S.M.; Tomkinson, K.N.; Monnell, T.E.; Spaits, M.S.; Kumar, R.; Underwood, K.W.; Pearsall, R.S.; Lachey, J.L. Administration of a Soluble Activin Type IIB Receptor Promotes Skeletal Muscle Growth Independent of Fiber Type. J. Appl. Physiol. 2010, 109, 635–642.
  89. Lawlor, M.W.; Read, B.P.; Edelstein, R.; Yang, N.; Pierson, C.R.; Stein, M.J.; Wermer-Colan, A.; Buj-Bello, A.; Lachey, J.L.; Seehra, J.S.; et al. Inhibition of Activin Receptor Type IIB Increases Strength and Lifespan in Myotubularin-Deficient Mice. Am. J. Pathol. 2011, 178, 784–793.
  90. Béchir, N.; Pecchi, É.; Relizani, K.; Vilmen, C.; Le Fur, Y.; Bernard, M.; Amthor, H.; Bendahan, D.; Giannesini, B. Mitochondrial Impairment Induced by Postnatal ActRIIB Blockade Does Not Alter Function and Energy Status in Exercising Mouse Glycolytic Muscle in Vivo. Am. J. Physiol.-Endocrinol. Metab. 2016, 310, E539–E549.
  91. Relizani, K.; Mouisel, E.; Giannesini, B.; Hourdé, C.; Patel, K.; Gonzalez, S.M.; Jülich, K.; Vignaud, A.; Piétri-Rouxel, F.; Fortin, D.; et al. Blockade of ActRIIB Signaling Triggers Muscle Fatigability and Metabolic Myopathy. Mol. Ther. 2014, 22, 1423–1433.
  92. Nagy, J.A.; Kapur, K.; Taylor, R.S.; Sanchez, B.; Rutkove, S.B. Electrical Impedance Myography as a Biomarker of Myostatin Inhibition with ActRIIB-MFc: A Study in Wild-Type Mice. Future Sci. OA 2018, 4, FSO308.
  93. Hoogaars, W.M.H.; Mouisel, E.; Pasternack, A.; Hulmi, J.J.; Relizani, K.; Schuelke, M.; Schirwis, E.; Garcia, L.; Ritvos, O.; Ferry, A.; et al. Combined Effect of AAV-U7-Induced Dystrophin Exon Skipping and Soluble Activin Type IIB Receptor in Mdx Mice. Hum. Gene Ther. 2012, 23, 1269–1279.
  94. Béchir, N.; Pecchi, É.; Vilmen, C.; Bernard, M.; Bendahan, D.; Giannesini, B. Activin Type IIB Receptor Blockade Does Not Limit Adenosine Triphosphate Supply in Mouse Skeletal Muscle in Vivo. Muscle Nerve 2018, 58, 834–842.
  95. Tauer, J.T.; Rauch, F. Novel ActRIIB Ligand Trap Increases Muscle Mass and Improves Bone Geometry in a Mouse Model of Severe Osteogenesis Imperfecta. Bone 2019, 128, 115036.
  96. Li, Z.B.; Zhang, J.; Wagner, K.R. Inhibition of Myostatin Reverses Muscle Fibrosis through Apoptosis. J. Cell Sci. 2012, 125, 3957–3965.
  97. Pistilli, E.E.; Bogdanovich, S.; Goncalves, M.D.; Ahima, R.S.; Lachey, J.; Seehra, J.; Khurana, T. Targeting the Activin Type IIB Receptor to Improve Muscle Mass and Function in the Mdx Mouse Model of Duchenne Muscular Dystrophy. Am. J. Pathol. 2011, 178, 1287–1297.
  98. Iskenderian, A.; Liu, N.; Deng, Q.; Huang, Y.; Shen, C.; Palmieri, K.; Crooker, R.; Lundberg, D.; Kastrapeli, N.; Pescatore, B.; et al. Myostatin and Activin Blockade by Engineered Follistatin Results in Hypertrophy and Improves Dystrophic Pathology in Mdx Mouse More than Myostatin Blockade Alone. Skelet. Muscle 2018, 8, 34.
  99. Hulmi, J.J.; Oliveira, B.M.; Silvennoinen, M.; Hoogaars, W.M.H.; Pasternack, A.; Kainulainen, H.; Ritvos, O. Exercise Restores Decreased Physical Activity Levels and Increases Markers of Autophagy and Oxidative Capacity in Myostatin/Activin-Blocked Mdx Mice. Am. J. Physiol.-Endocrinol. Metab. 2013, 305, E171–E182.
  100. Tinklenberg, J.; Meng, H.; Yang, L.; Liu, F.; Hoffmann, R.G.; Dasgupta, M.; Allen, K.P.; Beggs, A.H.; Hardeman, E.C.; Pearsall, R.S.; et al. Treatment with ActRIIB-MFc Produces Myofiber Growth and Improves Lifespan in the Acta1 H40Y Murine Model of Nemaline Myopathy. Am. J. Pathol. 2016, 186, 1568–1581.
  101. Lawlor, M.W.; Viola, M.G.; Meng, H.; Edelstein, R.V.; Liu, F.; Yan, K.; Luna, E.J.; Lerch-Gaggl, A.; Hoffmann, R.G.; Pierson, C.R.; et al. Differential Muscle Hypertrophy Is Associated with Satellite Cell Numbers and Akt Pathway Activation Following Activin Type IIB Receptor Inhibition in Mtm1 p.R69C Mice. Am. J. Pathol. 2014, 184, 1831–1842.
  102. Bondulich, M.K.; Jolinon, N.; Osborne, G.F.; Smith, E.J.; Rattray, I.; Neueder, A.; Sathasivam, K.; Ahmed, M.; Ali, N.; Benjamin, A.C.; et al. Myostatin Inhibition Prevents Skeletal Muscle Pathophysiology in Huntington’s Disease Mice. Sci. Rep. 2017, 7, 14275.
  103. Lee, Y.-S.; Lehar, A.; Sebald, S.; Liu, M.; Swaggart, K.A.; Talbot, C.C.; Pytel, P.; Barton, E.R.; McNally, E.M.; Lee, S.-J. Muscle Hypertrophy Induced by Myostatin Inhibition Accelerates Degeneration in Dysferlinopathy. Hum. Mol. Genet. 2015, 24, 5711–5719.
  104. Ohsawa, Y.; Hagiwara, H.; Nakatani, M.; Yasue, A.; Moriyama, K.; Murakami, T.; Tsuchida, K.; Noji, S.; Sunada, Y. Muscular Atrophy of Caveolin-3–Deficient Mice Is Rescued by Myostatin Inhibition. J. Clin. Investig. 2006, 116, 2924–2934.
  105. Lach-Trifilieff, E.; Minetti, G.C.; Sheppard, K.; Ibebunjo, C.; Feige, J.N.; Hartmann, S.; Brachat, S.; Rivet, H.; Koelbing, C.; Morvan, F.; et al. An Antibody Blocking Activin Type II Receptors Induces Strong Skeletal Muscle Hypertrophy and Protects from Atrophy. Mol. Cell Biol. 2014, 34, 606–618.
  106. Morvan, F.; Rondeau, J.-M.; Zou, C.; Minetti, G.; Scheufler, C.; Scharenberg, M.; Jacobi, C.; Brebbia, P.; Ritter, V.; Toussaint, G.; et al. Blockade of Activin Type II Receptors with a Dual Anti-ActRIIA/IIB Antibody Is Critical to Promote Maximal Skeletal Muscle Hypertrophy. Proc. Natl. Acad. Sci. USA 2017, 114, 12448–12453.
  107. Haidet, A.M.; Rizo, L.; Handy, C.; Umapathi, P.; Eagle, A.; Shilling, C.; Boue, D.; Martin, P.T.; Sahenk, Z.; Mendell, J.R.; et al. Long-Term Enhancement of Skeletal Muscle Mass and Strength by Single Gene Administration of Myostatin Inhibitors. Proc. Natl. Acad. Sci. USA 2008, 105, 4318–4322.
  108. Miller, T.M.; Kim, S.H.; Yamanaka, K.; Hester, M.; Umapathi, P.; Arnson, H.; Rizo, L.; Mendell, J.R.; Gage, F.H.; Cleveland, D.W.; et al. Gene Transfer Demonstrates That Muscle Is Not a Primary Target for Non-Cell-Autonomous Toxicity in Familial Amyotrophic Lateral Sclerosis. Proc. Natl. Acad. Sci. USA 2006, 103, 19546–19551.
  109. Kota, J.; Handy, C.R.; Haidet, A.M.; Montgomery, C.L.; Eagle, A.; Rodino-Klapac, L.R.; Tucker, D.; Shilling, C.J.; Therlfall, W.R.; Walker, C.M.; et al. Follistatin Gene Delivery Enhances Muscle Growth and Strength in Nonhuman Primates. Sci. Transl. Med. 2009, 1, 6ra15.
  110. Pearsall, R.S.; Davies, M.V.; Cannell, M.; Li, J.; Widrick, J.; Mulivor, A.W.; Wallner, S.; Troy, M.E.; Spaits, M.; Liharska, K.; et al. Follistatin-Based Ligand Trap ACE-083 Induces Localized Hypertrophy of Skeletal Muscle with Functional Improvement in Models of Neuromuscular Disease. Sci. Rep. 2019, 9, 1–14.
  111. Castonguay, R.; Lachey, J.; Wallner, S.; Strand, J.; Liharska, K.; Watanabe, A.E.; Cannell, M.; Davies, M.V.; Sako, D.; Troy, M.E.; et al. Follistatin-288-Fc Fusion Protein Promotes Localized Growth of Skeletal Muscle. J. Pharm. Exp. 2018, 365, 435–445.
  112. Foster, K.; Graham, I.R.; Otto, A.; Foster, H.; Trollet, C.; Yaworsky, P.J.; Walsh, F.S.; Bickham, D.; Curtin, N.A.; Kawar, S.L.; et al. Adeno-Associated Virus-8-Mediated Intravenous Transfer of Myostatin Propeptide Leads to Systemic Functional Improvements of Slow but Not Fast Muscle. Rejuvenation Res. 2009, 12, 85–94.
  113. Liu, M.; Hammers, D.W.; Barton, E.R.; Sweeney, H.L. Activin Receptor Type IIB Inhibition Improves Muscle Phenotype and Function in a Mouse Model of Spinal Muscular Atrophy. PLoS ONE 2016, 11, e0166803.
  114. Morine, K.J.; Bish, L.T.; Selsby, J.T.; Gazzara, J.A.; Pendrak, K.; Sleeper, M.M.; Barton, E.R.; Lee, S.-J.; Sweeney, H.L. Activin IIB Receptor Blockade Attenuates Dystrophic Pathology in a Mouse Model of Duchenne Muscular Dystrophy. Muscle Nerve 2010, 42, 722–730.
  115. Morine, K.J.; Bish, L.T.; Pendrak, K.; Sleeper, M.M.; Barton, E.R.; Sweeney, H.L. Systemic Myostatin Inhibition via Liver-Targeted Gene Transfer in Normal and Dystrophic Mice. PLoS ONE 2010, 5, e9176.
  116. Hammers, D.W.; Hart, C.C.; Patsalos, A.; Matheny, M.K.; Wright, L.A.; Nagy, L.; Sweeney, H.L. Glucocorticoids Counteract Hypertrophic Effects of Myostatin Inhibition in Dystrophic Muscle. JCI Insight 2020, 5.
  117. Bish, L.T.; Sleeper, M.M.; Forbes, S.C.; Morine, K.J.; Reynolds, C.; Singletary, G.E.; Trafny, D.; Pham, J.; Bogan, J.; Kornegay, J.N.; et al. Long-Term Systemic Myostatin Inhibition via Liver-Targeted Gene Transfer in Golden Retriever Muscular Dystrophy. Hum. Gene Ther. 2011, 22, 1499–1509.
  118. Lu-Nguyen, N.; Malerba, A.; Popplewell, L.; Schnell, F.; Hanson, G.; Dickson, G. Systemic Antisense Therapeutics for Dystrophin and Myostatin Exon Splice Modulation Improve Muscle Pathology of Adult Mdx Mice. Mol. Nucleic Acids 2017, 6, 15–28.
  119. Dumonceaux, J.; Marie, S.; Beley, C.; Trollet, C.; Vignaud, A.; Ferry, A.; Butler-Browne, G.; Garcia, L. Combination of Myostatin Pathway Interference and Dystrophin Rescue Enhances Tetanic and Specific Force in Dystrophic Mdx Mice. Mol. Ther. 2010, 18, 881–887.
  120. Mendias, C.L.; Marcin, J.E.; Calerdon, D.R.; Faulkner, J.A. Contractile Properties of EDL and Soleus Muscles of Myostatin-Deficient Mice. J. Appl. Physiol. (1985) 2006, 101, 898–905.
  121. Qaisar, R.; Renaud, G.; Morine, K.; Barton, E.R.; Sweeney, H.L.; Larsson, L. Is Functional Hypertrophy and Specific Force Coupled with the Addition of Myonuclei at the Single Muscle Fiber Level? FASEB J. 2011, 26, 1077–1085.
  122. Amthor, H.; Macharia, R.; Navarrete, R.; Schuelke, M.; Brown, S.C.; Otto, A.; Voit, T.; Muntoni, F.; Vrbóva, G.; Partridge, T.; et al. Lack of Myostatin Results in Excessive Muscle Growth but Impaired Force Generation. Proc. Natl. Acad. Sci. USA 2007, 104, 1835–1840.
  123. Girgenrath, S.; Song, K.; Whittemore, L.-A. Loss of Myostatin Expression Alters Fiber-Type Distribution and Expression of Myosin Heavy Chain Isoforms in Slow- and Fast-Type Skeletal Muscle. Muscle Nerve 2005, 31, 34–40.
  124. Hennebry, A.; Berry, C.; Siriett, V.; O’Callaghan, P.; Chau, L.; Watson, T.; Sharma, M.; Kambadur, R. Myostatin Regulates Fiber-Type Composition of Skeletal Muscle by Regulating MEF2 and MyoD Gene Expression. Am. J. Physiol.-Cell Physiol. 2009, 296, C525–C534.
  125. Hennebry, A.; Oldham, J.; Shavlakadze, T.; Grounds, M.D.; Sheard, P.; Fiorotto, M.L.; Falconer, S.; Smith, H.K.; Berry, C.; Jeanplong, F.; et al. IGF1 Stimulates Greater Muscle Hypertrophy in the Absence of Myostatin in Male Mice. J. Endocrinol. 2017, 234, 187–200.
  126. Matsakas, A.; Mouisel, E.; Amthor, H.; Patel, K. Myostatin Knockout Mice Increase Oxidative Muscle Phenotype as an Adaptive Response to Exercise. J. Muscle Res. Cell Motil. 2010, 31, 111–125.
  127. Kocsis, T.; Trencsenyi, G.; Szabo, K.; Baan, J.A.; Muller, G.; Mendler, L.; Garai, I.; Reinauer, H.; Deak, F.; Dux, L.; et al. Myostatin Propeptide Mutation of the Hypermuscular Compact Mice Decreases the Formation of Myostatin and Improves Insulin Sensitivity. Am. J. Physiol.-Endocrinol. Metab. 2016, 312, E150–E160.
  128. Wagner, K.R.; McPherron, A.C.; Winik, N.; Lee, S.-J. Loss of Myostatin Attenuates Severity of Muscular Dystrophy in Mdx Mice. Ann. Neurol. 2002, 52, 832–836.
  129. Wagner, K.R.; Liu, X.; Chang, X.; Allen, R.E. Muscle Regeneration in the Prolonged Absence of Myostatin. Proc. Natl. Acad. Sci. USA 2005, 102, 2519–2524.
  130. Li, Z.; Shelton, G.D.; Engvall, E. Elimination of Myostatin Does Not Combat Muscular Dystrophy in Dy Mice but Increases Postnatal Lethality. Am. J. Pathol. 2005, 166, 491–497.
  131. Stedman, H.H.; Sweeney, H.L.; Shrager, J.B.; Maguire, H.C.; Panettieri, R.A.; Petrof, B.; Narusawa, M.; Leferovich, J.M.; Sladky, J.T.; Kelly, A.M. The Mdx Mouse Diaphragm Reproduces the Degenerative Changes of Duchenne Muscular Dystrophy. Nature 1991, 352, 536–539.
  132. Long, K.K.; O’Shea, K.M.; Khairallah, R.J.; Howell, K.; Paushkin, S.; Chen, K.S.; Cote, S.M.; Webster, M.T.; Stains, J.P.; Treece, E.; et al. Specific Inhibition of Myostatin Activation Is Beneficial in Mouse Models of SMA Therapy. Hum. Mol. Genet. 2019, 28, 1076–1089.
  133. Graham, Z.A.; Collier, L.; Peng, Y.; Saéz, J.C.; Bauman, W.A.; Qin, W.; Cardozo, C.P. A Soluble Activin Receptor IIB Fails to Prevent Muscle Atrophy in a Mouse Model of Spinal Cord Injury. J. Neurotrauma 2016, 33, 1128–1135.
  134. Pistilli, E.E.; Bogdanovich, S.; Mosqueira, M.; Lachey, J.; Seehra, J.; Khurana, T.S. Pretreatment with a Soluble Activin Type IIB Receptor/Fc Fusion Protein Improves Hypoxia-Induced Muscle Dysfunction. Am. J. Physiol.-Regul. Integr. Comp. Physiol. 2010, 298, R96–R103.
  135. Tortoriello, D.V.; Sidis, Y.; Holtzman, D.A.; Holmes, W.E.; Schneyer, A.L. Human Follistatin-Related Protein: A Structural Homologue of Follistatin with Nuclear Localization. Endocrinology 2001, 142, 3426–3434.
  136. Nakatani, M.; Takehara, Y.; Sugino, H.; Matsumoto, M.; Hashimoto, O.; Hasegawa, Y.; Murakami, T.; Uezumi, A.; Takeda, S.; Noji, S.; et al. Transgenic Expression of a Myostatin Inhibitor Derived from Follistatin Increases Skeletal Muscle Mass and Ameliorates Dystrophic Pathology in Mdx Mice. FASEB J. 2008, 22, 477–487.
  137. Shen, C.; Iskenderian, A.; Lundberg, D.; He, T.; Palmieri, K.; Crooker, R.; Deng, Q.; Traylor, M.; Gu, S.; Rong, H.; et al. Protein Engineering on Human Recombinant Follistatin: Enhancing Pharmacokinetic Characteristics for Therapeutic Application. J. Pharm. Exp. 2018, 366, 291–302.
  138. Malerba, A.; Kang, J.K.; McClorey, G.; Saleh, A.F.; Popplewell, L.; Gait, M.J.; Wood, M.J.; Dickson, G. Dual Myostatin and Dystrophin Exon Skipping by Morpholino Nucleic Acid Oligomers Conjugated to a Cell-Penetrating Peptide Is a Promising Therapeutic Strategy for the Treatment of Duchenne Muscular Dystrophy. Mol. Nucleic. Acids 2012, 1, e62.
  139. Varga, L.; Szabo, G.; Darvasi, A.; Muller, G.; Sass, M.; Soller, M. Inheritance and Mapping of Compact (Cmpt), a New Mutation Causing Hypermuscularity in Mice. Genetics 1997, 147, 755–764.
  140. Wilkes, J.J.; Lloyd, D.J.; Gekakis, N. Loss-of-Function Mutation in Myostatin Reduces Tumor Necrosis Factor Alpha Production and Protects Liver against Obesity-Induced Insulin Resistance. Diabetes 2009, 58, 1133–1143.
  141. Kramerova, I.; Marinov, M.; Owens, J.; Lee, S.-J.; Becerra, D.; Spencer, M.J. Myostatin Inhibition Promotes Fast Fibre Hypertrophy but Causes Loss of AMP-Activated Protein Kinase Signalling and Poor Exercise Tolerance in a Model of Limb-Girdle Muscular Dystrophy R1/2A. J. Physiol. 2020, 598, 3927–3939.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
Feedback